Screener / SEC EDGAR /CIK 0001756262 /10-K filed Feb 24, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Devices

TransMedics Group, Inc. TMDX

Compare with peers Embed
Earnings releases

Latest results release: Nov 5, 2026

8-K item 2.02, exhibit 99

What TMDX's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

To calculate adjusted income from operations, adjusted operating margin, adjusted net income and adjusted diluted net income per common share, we exclude certain charges (credits) from GAAP income from operations and GAAP net income, such as transaction-related costs, incremental amortization of intangible assets, ERP implementation costs, headquarters relocation costs, legal matters and discrete tax items. release Nov 5, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 5, 2026 · EX-99.1

TransMedics Reports Third Quarter 2026 Financial Results

Open on SEC

Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts

Andover, Mass. –November 5, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2026.

Total revenue of $203.0 million, up 41%, including organic revenue growth* of 35%

Product revenue of $113.4 million, up 29%, and service revenue of $89.6 million, up 60%, including organic service revenue growth* of 43%

Net income of $17.1 million or $0.46 per diluted share in the third quarter of 2026

Adjusted net income* of $18.9 million or $0.51 per diluted share in the third quarter of 2026

Raises full-year 2026 revenue guidance to between $764-$774 million, inclusive of approximately $14 million from PAD Aviation

Completed enrollment in Part A of the Next-Generation Organ Care System (OCS) ENHANCE Heart trial (September) and received U.S. Food and Drug Administration (FDA) approval of a continued access protocol, allowing enrollment of an additional 90 patients (October)

Received Investigational Device Exemption (IDE) approvals from U.S. FDA for ENHANCE Heart Part B and DENOVO Lung trials, including use of TransMedics Controlled Hypothermic Organ Preservation System (CHOPS) as a control arm for both trials (October)

Awarded first European transplant logistics tender in Italy, commencing the company’s European transplant operations using PAD Aviation (October)

Appointed Fernando Araujo, former CFO of GE HealthCare's Advanced Imaging Solutions segment, as Chief Financial Officer (September)

“The third quarter of 2026 was the strongest in TransMedics’ history, with record revenue and record case volume. Importantly, we delivered these results despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO.” said Waleed Hassanein, MD, President and Chief Executive Officer. “We enter 2027 with strong momentum and a robust set of growth catalysts. ENHANCE Heart Part B and DENOVO Lung target large, untapped heart and lung segments, with two shots on goal in each through OCS and CHOPS. In Europe, we plan to launch OCS NOP in Italy, the Netherlands and Belgium, building on our first European transplant logistics win. And OCS Kidney remains on track for first-in-human clinical experience in the second half of 2027, our path into the largest transplant market. Our strategy is clear. Our execution is proven. Our conviction has never been stronger. We are building the global platform to transform organ transplantation, and we strongly believe our best years are still ahead.” Recent IDE Approvals In October, TransMedics received full U.S. Food and Drug Administration (FDA) IDE approvals for Part B of the OCS ENHANCE Heart trial and DENOVO Lung trial as the company further advances its OCS platform into new indications, seeks to capture new commercial opportunity, and addresses patient needs. EU Expansion TransMedics continues to expand its operations in the EU, including through winning its first logistics tender in Italy. This milestone supports the company’s growth strategy into key European markets and follows the establishment of its dedicated organ transplantation air logistics network through the recent strategic investment in PAD Aviation. Third Quarter 2026 Financial Results A summary of third quarter financial results is as follows (dollars in thousands except per share):

(1) Adjusted income from operations, adjusted operating margin and adjusted diluted net income per share represent non-GAAP financial measures. For a reconciliation of GAAP to non-GAAP items, please see the tables attached to this press release. Total revenue for the third quarter of 2026 was $203.0 million, a 41% increase compared to $143.8 million in the third quarter of 2025. The increase was due primarily to increasing Liver and Heart volume through the National OCS Program (“NOP”) as well as additional revenue generated by TransMedics logistics services, and the contribution of PAD Aviation following the Company's strategic investment on July 1, 2026. Gross margin was 58.5%, compared with 58.8% in the prior-year period. The year-over-year decrease primarily reflected a higher mix of service revenue, partly offset by reduced scrap, lower inventory adjustments and logistics efficiencies resulting from pricing improvements across both service and logistics operations, productivity gains from reduced supplemental lift utilization, lower ground transportation cost per mission, and improved leverage of fixed operating costs as volume increased. Operating expenses for the third quarter of 2026 were $90.5 million compared to $61.3 million in the third quarter of 2025. The increase in operating expenses was driven by planned investment in OCS Kidney, Next-Generation OCS, and ENHANCE clinical programs, increased headcount to support development activities and company’s expansion, and infrastructure investments, including the US Headquarters and the addition of PAD Aviation. Third quarter operating expenses in 2026 included $12.1 million of stock compensation expense compared to $8.7 million of stock compensation expense in the third quarter of 2025. Income from operations in the third quarter of 2026 was $28.1 million, compared to operating income of $23.3 million in the third quarter of 2025. Adjusted income from operations in the third quarter of 2026 was $28.9 million compared to adjusted income from operations of $23.6 million in the third quarter of 2025. Net income in the third quarter of 2026 was $17.1 million, or $0.46 per diluted share, compared to net income of $24.3 million, or $0.66 per diluted share, in the third quarter of 2025. Adjusted net income in the third quarter of 2026 was $18.9 million, or $0.51 per diluted share compared to adjusted net income of $24.5 million, or $0.67 per diluted share, in the third quarter of 2025. Cash was $493.0 million as of September 30, 2026. 2026 Financial Outlook TransMedics raises its full-year 2026 revenue guidance. The table below summarizes the updates:

Implied Annual Prior Guidance Updated Guidance Growth(compared to FY 2025 revenue) FY 2026 Revenue(excluding $737-$757 million $750-$760 million 24% to 26% PAD Aviation) FY 2026 Revenue(including --- $764-$774 million 26% to 28% PAD Aviation)

Webcast and Conference Call Details The TransMedics management team will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT on Thursday, November 5, 2026. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 6054544. A live and archived webcast of the event and the company’s slide presentation with information on third quarter 2026 financial results will be available on the “Investors” section of the TransMedics website at www.transmedics.com . About TransMedics Group, Inc. TransMedics is the world’s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. TransMedics routinely posts information that may be important to investors on the landing page of the Company's website and in the "Investors" section of the website at https://investors.transmedics.com/. Investors and potential investors are encouraged to consult the TransMedics website regularly for important information about TransMedics. This press release contains forward-looking statements with respect to, among other things, future results and events, including financial guidance and projected estimates, potential clinical outcomes and therapies, and statements about our operations, operational execution, financial position, strategic plans and other business plans. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “could,” “target,” “predict,” “seek”, “look to”, “plan” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward- looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: the fluctuation of our financial results from quarter to quarter; our ability to attract, train and retain key personnel; our dependence on the success of the OCS; our ability to expand access to the OCS through our NOP; our ability to improve the OCS platform, including by developing the next generation of the OCS products or expanding into new indications and the development and potential commercialization of our OCS Kidney device; the timing or results of clinical trials for the OCS, including pre- and post-approval studies, or other product candidates, including CHOPS; our ability to sustain profitability; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; that we have identified a material weakness in our internal control over financial reporting, and that we may identify additional material weaknesses in the future; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States, the European Union and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration (the “FDA”) or other competent authorities, follow-up inquiries in a timely manner; the impact of healthcare policy changes, including recently enacted or potential future legislation or administrative actions affecting or reforming the U.S. healthcare system, Organ Procurement and Transplantation Network, or the FDA; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our transplant logistics capabilities to support our NOP to reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration, or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology, or IT, infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products or services infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the impact of a shutdown of the U.S. government; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreements to which we will remain subject until maturity; the impact of any product recalls or improper use of our products; the outcome of our securities class action litigation; our international expansion plans and the costs related thereto; the ability to integrate our completed or future acquisitions, joint ventures, and strategic investments, including PAD Aviation; our estimates regarding revenue, expenses and needs for additional financing; our ability to achieve our revenue guidance, which assumes, among other things, continued growth in organ utilization and OCS adoption and the contribution of PAD Aviation; changes in our mix of product and service revenue and the resulting effect on our gross margin; our finance lease obligations; the impact of the Centers for Medicare & Medicaid Services final rule on Organ Procurement Organization Conditions for Coverage (CMS-3409-F) released October 30, 2026; and the other factors described under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and our subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”), and in our other SEC filings. Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward- looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. To supplement our consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we disclose certain non-GAAP financial measures, including organic revenue, organic revenue growth, organic service revenue, organic service revenue growth, revenue guidance excluding PAD Aviation, adjusted income from operations, adjusted operating margin, adjusted net income, and adjusted diluted net income per common share. These non-GAAP financial measures are not calculated in accordance with GAAP, are not a substitute for, and should be considered supplemental to, GAAP financial measures. Our definitions of these non-GAAP measures may differ from similarly titled measures used by other companies, which may limit their usefulness for comparative purposes.

We use these non-GAAP financial measures for financial and operational decision- making and as a means to evaluate period-to-period comparisons. We believe the presentation of these measures is useful to both management and investors as they provide meaningful supplemental information with respect to our core operational performance and allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

We report organic revenue, organic revenue growth, organic service revenue, organic service revenue growth and revenue guidance excluding PAD Aviation to provide management and investors with additional understanding and visibility into the underlying revenue trends of the Company’s established, ongoing operations, as well as provide insights into overall demand for its products and services. To calculate these measures, we exclude from revenue and service revenue the effect of the PAD Aviation transaction as there is no prior period comparable revenue.

To calculate adjusted income from operations, adjusted operating margin, adjusted net income and adjusted diluted net income per common share, we exclude certain charges (credits) from GAAP income from operations and GAAP net income, such as transaction-related costs, incremental amortization of intangible assets, ERP implementation costs, headquarters relocation costs, legal matters and discrete tax items. Amounts are presented after-tax using the company's statutory tax rate unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate.”

TransMedics Group, Inc. Consolidated Statements of Operations (in thousands, except share and per share data) · (unaudited)

TransMedics Group, Inc. Condensed Consolidated Balance Sheets (in thousands) · (unaudited)

September 30, December 31, 2026 2025 Assets Current assets: Cash $492,962 $488,366 Accounts receivable 114,935 84,282 Inventory 58,373 48,881 Prepaid expenses and other current assets 26,186 16,254 Total current assets 692,456 637,783 Property, plant and equipment, net 376,490 327,656 Finance lease right-of-use assets, net 330,400 — Operating lease right-of-use assets, net 4,342 5,155 Deferred tax assets 72,787 83,543 Restricted cash 18,438 500 Goodwill 18,015 11,549 Acquired intangible assets, net 2,815 1,948 Other non-current assets 2,194 239 Total assets $1,517,937 $1,068,373 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $10,143 $10,350 Accrued expenses and other current liabilities 82,757 62,740 Current portion of long-term debt, net 54,818 10,000 Deferred revenue 1,497 2,905 Operating lease liabilities 3,642 3,310 Total current liabilities 152,857 89,305 Convertible senior notes, net 454,994 452,804 Long-term debt, net — 49,587 Finance lease liability 351,533 — Operating lease liabilities, net of current 1,915 3,577 portion Other long-term liabilities 5,926 — Total liabilities 967,225 595,273 Total stockholders’ equity 550,712 473,100 Total liabilities and stockholders’ equity $1,517,937 $1,068,373

TransMedics Group, Inc. Non-GAAP Income From Operations, Net Income and Diluted Net Income per Share Reconciliations (dollars in thousands, except per share) · (unaudited)

Three Months Diluted Ended NetIncome September 30, Income OperatingMargin perCommon 2026 fromOperations % Net Income Share ────────────────────────────────────────────────────────────────────────────── Reported $28,141 13.9% $17,073 $0.46 Non-GAAP adjustments: Transaction-r… 667 0.3% 667 0.02 costs(1) ERP implementation 64 0.0% 48 — costs(2) Discrete tax — 0.0% 1,125 0.03 items(3) Adjusted $28,872 14.2% $18,913 $0.51 Nine Months Ended September 30, 2026 Reported $65,174 11.5% $39,070 $1.08 Non-GAAP adjustments: Transaction-r… 5,119 0.9% 3,994 0.10 costs(1) Headquarters relocation 272 0.0% 204 0.01 costs(4) ERP implementation 309 0.1% 231 0.01 costs(2) Incremental amortization of acquired 1,898 0.3% 1,418 0.03 intangible assets(5) Discrete tax — 0.0% 1,125 0.03 items(3) Adjusted $72,772 12.8% $46,042 $1.26* * As a result of our non-GAAP adjustments, our convertible senior notes have a dilutive effect for the nine months ended September 30, 2026, for the purposes of calculating adjusted diluted EPS. Our adjusted diluted EPS includes an addback of $5.5 million of interest expense, net of tax, attributable to assumed conversion of convertible senior notes, and an inclusion of an additional 4,893,805 shares to our diluted weighted-aver… common shares outstanding. Refer Footnote 10 within our 10-Q filed with the SEC on November 5, 2026 for additional details on our net income per share calculation on a GAAP basis. Three Months Ended September 30, 2025 Reported $23,300 16.2% $24,319 $0.66 Non-GAAP adjustments: Headquarters relocation 115 0.1% 86 — costs(4) ERP implementation 156 0.1% 117 0.01 costs(2) Adjusted $23,571 16.4% $24,522 $0.67 Nine Months Ended September 30, 2025 Reported $87,310 19.6% $84,908 $2.28 Non-GAAP adjustments: Headquarters relocation 115 0.0% 86 — costs(4) ERP implementation 156 0.0% 117 0.01 costs(2) Legal 2,358 0.6% 1,759 0.04 matters(6) Adjusted $89,939 20.2% $86,870 $2.33

(1) Transaction-related costs – These adjustments primarily reflect direct and incremental costs incurred in connection with strategic initiatives and corporate development activities, and may include due diligence, deal fees, integration and other fees and costs related to transactions. The Company excludes only costs that are directly attributable to individually identifiable transactions that have progressed beyond preliminary evaluation, including those for which formal internal approvals have been obtained or third-party advisors have been engaged. Exploratory and other ongoing corporate development and strategy-related operating expenses are not excluded. Excluded costs are associated with discrete transaction events and are not reflective of the Company’s core operating performance, although similar costs may be incurred in future periods. (2) ERP implementation costs – These adjustments reflect direct and incremental costs incurred in connection with the design, configuration, testing, deployment, and initial implementation of a new enterprise resource planning (“ERP”) system, or a significant upgrade or replacement of an existing ERP platform. Such costs may include third-party consulting, system integration, project management, data conversion, and other implementation-related professional fees. The Company excludes only costs that are directly attributable to the initial implementation or significant transformation of an ERP platform and that are non-recurring in nature. Ongoing software subscription, hosting, maintenance, support, personnel, and other recurring information technology operating expenses are not excluded. (3) Discrete tax items – These adjustments represent certain income tax charges or benefits that management does not consider indicative of ongoing operating performance. Such items may include the indirect tax consequences of non-GAAP adjustments affecting the utilization of tax credits, deductions or other tax benefits; tax effects recognized in the current period related to non-GAAP adjustments recorded in prior periods; and certain significant tax adjustments arising from changes in tax laws, valuation allowances, tax settlements or other discrete tax events, as applicable. These items are excluded from adjusted net income and adjusted earnings per share to facilitate comparability of operating performance between periods. (4) Headquarters relocation costs – These adjustments reflect primarily direct and incremental third-party professional fees, including valuation, accounting, and advisory services, incurred in connection with the Company’s relocation of its headquarters to Somerville, Massachusetts. These costs may also include incremental depreciation of fixed assets resulting from reassessments of estimated economic lives in consideration of the relocation. The Company excludes only costs that are directly attributable to the relocation event and does not exclude ongoing occupancy, personnel, or other recurring operating expenses associated with the new headquarters. (5) Incremental amortization of acquired intangible assets – We record intangible assets acquired in a business combination or asset acquisition at acquisition date fair values and amortize over their estimated useful lives. These adjustments reflect non-cash charges related to incremental amortization of acquired intangible assets, resulting from periodic reassessments of estimated economic lives. These amounts are excluded as they relate to discrete, non-routine activities rather than the Company’s ongoing operations and therefore are not considered indicative of normal operating costs. (6) Legal matters - These adjustments reflect legal fees and other directly attributable costs incurred in connection with responding to and addressing matters arising from the short-seller report issued in January 2025. Such costs may include external legal counsel, advisory services, and other incremental expenses necessary to evaluate and defend against the claims. The Company excludes only costs that are specifically associated with this discrete event and does not exclude ongoing legal expenses related to normal business operations. These costs are excluded as they are non- recurring in nature and not indicative of the Company’s core operating performance, although similar costs could arise in future periods. (7) Reconciliation of revenue to organic revenue and of service revenue to organic service revenue (dollars in thousands) (unaudited).

(8) Full-Year 2026 Revenue Guidance: Revenue guidance of $764-$774 million, less expected PAD Aviation revenue of approximately $14 million, equals revenue guidance excluding PAD Aviation* of $750-$760 million.

Full text with the tables
                
  Exhibit 99.1  
                
PRESS RELEASE                                                                   
                                                                                
   TransMedics Reports Third Quarter 2026 Financial Results                     
                                                                                
Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent    
Progress Positions Company for Continued Growth with Several Near- and Mid-Term 
Catalysts                                                                       
                                                                                
Andover, Mass. –November 5, 2026 – TransMedics Group, Inc. (“TransMedics”)      
(Nasdaq: TMDX), a medical technology company that is transforming organ         
transplant therapy for patients with end-stage lung, heart, and liver failure,  
today reported financial results for the quarter ended September 30, 2026.      
                                                                                
   Third Quarter 2026 Financial Highlights                                      
                                                                                
Total revenue of $203.0 million, up 41%, including organic revenue growth* of   
35%                                                                             
                                                                                
Product revenue of $113.4 million, up 29%, and service revenue of $89.6 million,
up 60%, including organic service revenue growth* of 43%                        
                                                                                
Net income of $17.1 million or $0.46 per diluted share in the third quarter of  
2026                                                                            
                                                                                
Adjusted net income* of $18.9 million or $0.51 per diluted share in the third   
quarter of 2026                                                                 
                                                                                
Raises full-year 2026 revenue guidance to between $764-$774 million, inclusive  
of approximately $14 million from PAD Aviation                                  
                                                                                
   Recent Business Highlights                                                   
                                                                                
Completed enrollment in Part A of the Next-Generation Organ Care System (OCS)   
ENHANCE Heart trial (September) and received U.S. Food and Drug Administration  
(FDA) approval of a continued access protocol, allowing enrollment of an        
additional 90 patients (October)                                                
                                                                                
Received Investigational Device Exemption (IDE) approvals from U.S. FDA for     
ENHANCE Heart Part B and DENOVO Lung trials, including use of TransMedics       
Controlled Hypothermic Organ Preservation System (CHOPS) as a control arm for   
both trials (October)                                                           
                                                                                
Awarded first European transplant logistics tender in Italy, commencing the     
company’s European transplant operations using PAD Aviation (October)           
                                                                                
Appointed Fernando Araujo, former CFO of GE HealthCare's Advanced Imaging       
Solutions segment, as Chief Financial Officer (September)                       
                                                                                
“The third quarter of 2026 was the strongest in TransMedics’ history, with      
record revenue and record case volume. Importantly, we delivered these results  
despite typical third quarter seasonality and before any contribution from      
ENHANCE Part B or DENOVO.” said Waleed Hassanein, MD, President and Chief       
Executive Officer. “We enter 2027 with strong momentum and a robust set of      
growth catalysts. ENHANCE Heart Part B and DENOVO Lung target large, untapped   
heart and lung segments, with two shots on goal in each through OCS and CHOPS.  
In Europe, we plan to launch OCS NOP in Italy, the Netherlands and Belgium,     
building on our first European transplant logistics win. And OCS Kidney remains 
on track for first-in-human clinical experience in the second half of 2027, our 
path into the largest transplant market. Our strategy is clear. Our execution is
proven. Our conviction has never been stronger. We are building the global      
platform to transform organ transplantation, and we strongly believe our best   
years are still ahead.”                                                         
Recent IDE Approvals In October, TransMedics received full U.S. Food and Drug
Administration (FDA) IDE approvals for Part B of the OCS ENHANCE Heart trial and
DENOVO Lung trial as the company further advances its OCS platform into new
indications, seeks to capture new commercial opportunity, and addresses patient
needs. EU Expansion TransMedics continues to expand its operations in the EU,
including through winning its first logistics tender in Italy. This milestone
supports the company’s growth strategy into key European markets and follows the
establishment of its dedicated organ transplantation air logistics network
through the recent strategic investment in PAD Aviation. Third Quarter 2026
Financial Results A summary of third quarter financial results is as follows
(dollars in thousands except per share):
                                                                                
                    Three                      Nine Months                      
                   Months                            Ended                      
                    Ended                        September                      
                September                              30,                      
                      30,                                                       
                     2026      2025  % Change         2026      2025  % Change  
  Revenue        $203,005  $143,823  41%          $566,886  $444,730  27%       
  Income                                                                        
  from            $28,141   $23,300  21%           $65,174   $87,310  -25%      
  operations                                                                    
  Operating         13.9%     16.2%  -230bps         11.5%     19.6%  -810bps   
  margin %                                                                      
  Adjusted                                                                      
  income          $28,872   $23,571  22%           $72,772   $89,939  -19%      
  from                                                                          
  operation…                                                                    
  Adjusted                                                                      
  operating         14.2%     16.4%  -220bps         12.8%     20.2%  -740bps   
  margin                                                                        
  %(1)                                                                          
  Diluted                                                                       
  net income        $0.46     $0.66  -30%            $1.08     $2.28  -53%      
  per share                                                                     
  Adjusted                                                                      
  diluted                                                                       
  net income        $0.51     $0.67  -24%            $1.26     $2.33  -46%      
  per                                                                           
  share(1)                                                                      
                                                                                
(1) Adjusted income from operations, adjusted operating margin and adjusted
diluted net income per share represent non-GAAP financial measures. For a
reconciliation of GAAP to non-GAAP items, please see the tables attached to this
press release. Total revenue for the third quarter of 2026 was $203.0 million, a
41% increase compared to $143.8 million in the third quarter of 2025. The
increase was due primarily to increasing Liver and Heart volume through the
National OCS Program (“NOP”) as well as additional revenue generated by
TransMedics logistics services, and the contribution of PAD Aviation following
the Company's strategic investment on July 1, 2026. Gross margin was 58.5%,
compared with 58.8% in the prior-year period. The year-over-year decrease
primarily reflected a higher mix of service revenue, partly offset by reduced
scrap, lower inventory adjustments and logistics efficiencies resulting from
pricing improvements across both service and logistics operations, productivity
gains from reduced supplemental lift utilization, lower ground transportation
cost per mission, and improved leverage of fixed operating costs as volume
increased.
Operating expenses for the third quarter of 2026 were $90.5 million compared to
$61.3 million in the third quarter of 2025. The increase in operating expenses
was driven by planned investment in OCS Kidney, Next-Generation OCS, and ENHANCE
clinical programs, increased headcount to support development activities and
company’s expansion, and infrastructure investments, including the US
Headquarters and the addition of PAD Aviation. Third quarter operating expenses
in 2026 included $12.1 million of stock compensation expense compared to $8.7
million of stock compensation expense in the third quarter of 2025. Income from
operations in the third quarter of 2026 was $28.1 million, compared to operating
income of $23.3 million in the third quarter of 2025. Adjusted income from
operations in the third quarter of 2026 was $28.9 million compared to adjusted
income from operations of $23.6 million in the third quarter of 2025. Net income
in the third quarter of 2026 was $17.1 million, or $0.46 per diluted share,
compared to net income of $24.3 million, or $0.66 per diluted share, in the
third quarter of 2025. Adjusted net income in the third quarter of 2026 was
$18.9 million, or $0.51 per diluted share compared to adjusted net income of
$24.5 million, or $0.67 per diluted share, in the third quarter of 2025. Cash
was $493.0 million as of September 30, 2026. 2026 Financial Outlook TransMedics
raises its full-year 2026 revenue guidance. The table below summarizes the
updates:
                                                                                
                                                           Implied Annual       
                     Prior Guidance     Updated Guidance   Growth(compared to   
                                                           FY 2025 revenue)     
  FY 2026                                                                       
  Revenue(excluding  $737-$757 million  $750-$760 million  24% to 26%           
  PAD Aviation)                                                                 
  FY 2026                                                                       
  Revenue(including  ---                $764-$774 million  26% to 28%           
  PAD Aviation)                                                                 
                                                                                
Webcast and Conference Call Details The TransMedics management team will host a
conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT on Thursday, November
5, 2026. Investors interested in listening to the conference call may do so by
dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international
callers and providing access code 6054544. A live and archived webcast of the
event and the company’s slide presentation with information on third quarter
2026 financial results will be available on the “Investors” section of the
TransMedics website at www.transmedics.com . About TransMedics Group, Inc.
TransMedics is the world’s leader in portable extracorporeal warm perfusion and
assessment of donor organs for transplantation. Headquartered in Andover,
Massachusetts, the company was founded to address the unmet need for more and
better organs for transplantation and has developed technologies to preserve
organ quality, assess organ viability prior to transplant, and potentially
increase the utilization of donor organs for the treatment of end-stage heart,
lung, and liver failure. TransMedics routinely posts information that may be
important to investors on the landing page of the Company's website and in the
"Investors" section of the website at https://investors.transmedics.com/.
Investors and potential investors are encouraged to consult the TransMedics
website regularly for important information about TransMedics.
This press release contains forward-looking statements with respect to, among   
other things, future results and events, including financial guidance and       
projected estimates, potential clinical outcomes and therapies, and statements  
about our operations, operational execution, financial position, strategic plans
and other business plans. For this purpose, all statements other than statements
of historical facts are forward-looking statements. The words “believe,” “may,” 
“will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,”     
“could,” “target,” “predict,” “seek”, “look to”, “plan” and similar expressions 
are intended to identify forward-looking statements. These forward-looking      
statements are subject to a number of risks and uncertainties. Our management   
cannot predict all risks, nor can we assess the impact of all factors or the    
extent to which any factor, or combination of factors, may cause actual results 
to differ materially from those contained in or implied by any forward-looking  
statements we may make. In light of these risks and uncertainties, the forward- 
looking events and circumstances discussed in this press release may not occur  
and actual results could differ materially and adversely from those anticipated 
in or implied by the forward-looking statements. Some of the key factors that   
could cause actual results to differ include: the fluctuation of our financial  
results from quarter to quarter; our ability to attract, train and retain key   
personnel; our dependence on the success of the OCS; our ability to expand      
access to the OCS through our NOP; our ability to improve the OCS platform,     
including by developing the next generation of the OCS products or expanding    
into new indications and the development and potential commercialization of our 
OCS Kidney device; the timing or results of clinical trials for the OCS,        
including pre- and post-approval studies, or other product candidates, including
CHOPS; our ability to sustain profitability; our need to raise additional       
funding and our ability to obtain it on favorable terms, or at all; our ability 
to use net operating losses and research and development credit carryforwards;  
that we have identified a material weakness in our internal control over        
financial reporting, and that we may identify additional material weaknesses in 
the future; our ability to scale our manufacturing and sterilization            
capabilities to meet increasing demand for our products; the rate and degree of 
market acceptance of the OCS; our ability to educate patients, surgeons,        
transplant centers and private and public payors on the benefits offered by the 
OCS; our dependence on a limited number of customers for a significant portion  
of our revenue; our ability to maintain regulatory approvals or clearances for  
our OCS products in the United States, the European Union and other select      
jurisdictions worldwide; our ability to adequately respond to the Food and Drug 
Administration (the “FDA”) or other competent authorities, follow-up inquiries  
in a timely manner; the impact of healthcare policy changes, including recently 
enacted or potential future legislation or administrative actions affecting or  
reforming the U.S. healthcare system, Organ Procurement and Transplantation     
Network, or the FDA; the performance of our third-party suppliers and           
manufacturers; our use of third parties to transport donor organs and medical   
personnel for our NOP and our ability to maintain and grow our transplant       
logistics capabilities to support our NOP to reduce dependence on third party   
transportation, including by means of attracting, training and retaining pilots,
and the acquisition, maintenance or replacement of fixed-wing aircraft for our  
aviation transportation services or other acquisitions, joint ventures or       
strategic investments; our ability to maintain Federal Aviation Administration, 
or other regulatory licenses or approvals for our aircraft transportation       
services; price increases of the components of our products and maintenance,    
parts and fuel for our aircraft; our manufacturing, sales, marketing and        
clinical support capabilities and strategy; attacks against our information     
technology, or IT, infrastructure; the economic, political and other risks      
associated with our foreign operations; our ability to protect, defend, maintain
and enforce our intellectual property rights relating to the OCS and avoid      
allegations that our products or services infringe, misappropriate or otherwise 
violate the intellectual property rights of third parties; the pricing of the   
OCS, as well as the reimbursement coverage for the OCS in the United States and 
internationally; regulatory developments in the United States, European Union   
and other jurisdictions; the impact of a shutdown of the U.S. government; the   
extent and success of competing products or procedures that are or may become   
available; our ability to service our 1.50% convertible senior notes, due 2028; 
our existing and any future indebtedness, including our ability to comply with  
affirmative and negative covenants under our credit agreements to which we will 
remain subject until maturity; the impact of any product recalls or improper use
of our products; the outcome of our securities class action litigation; our     
international expansion plans and the costs related thereto; the ability to     
integrate our completed or future acquisitions, joint ventures, and strategic   
investments, including PAD Aviation; our estimates regarding revenue, expenses  
and needs for additional financing; our ability to achieve our revenue guidance,
which assumes, among other things, continued growth in organ utilization and OCS
adoption and the contribution of PAD Aviation; changes in our mix of product and
service revenue and the resulting effect on our gross margin; our finance lease 
obligations; the impact of the Centers for Medicare & Medicaid Services final   
rule on Organ Procurement Organization Conditions for Coverage (CMS-3409-F)     
released October 30, 2026; and the other factors described under “Risk Factors” 
in our Annual Report on Form 10-K for the year ended December 31, 2025 and our  
subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange
Commission (the “SEC”), and in our other SEC filings. Additional information    
will be made available in our annual and quarterly reports and other filings    
that we make with the SEC. The forward-looking statements in this press release 
speak only as of the date of this press release. Factors or events that could   
cause our actual results to differ may emerge from time to time, and we are not 
able to predict all of them. We undertake no obligation to update any forward-  
looking statement, whether as a result of new information, future developments  
or otherwise, except as may be required by applicable law.                      
To supplement our consolidated financial statements, which are prepared and     
presented in accordance with generally accepted accounting principles in the    
United States (“GAAP”), we disclose certain non-GAAP financial measures,        
including organic revenue, organic revenue growth, organic service revenue,     
organic service revenue growth, revenue guidance excluding PAD Aviation,        
adjusted income from operations, adjusted operating margin, adjusted net income,
and adjusted diluted net income per common share. These non-GAAP financial      
measures are not calculated in accordance with GAAP, are not a substitute for,  
and should be considered supplemental to, GAAP financial measures. Our          
definitions of these non-GAAP measures may differ from similarly titled measures
used by other companies, which may limit their usefulness for comparative       
purposes.                                                                       
                                                                                
We use these non-GAAP financial measures for financial and operational decision-
making and as a means to evaluate period-to-period comparisons. We believe the  
presentation of these measures is useful to both management and investors as    
they provide meaningful supplemental information with respect to our core       
operational performance and allow for greater transparency with respect to key  
metrics used by management in its financial and operational decision-making.    
                                                                                
We report organic revenue, organic revenue growth, organic service revenue,     
organic service revenue growth and revenue guidance excluding PAD Aviation to   
provide management and investors with additional understanding and visibility   
into the underlying revenue trends of the Company’s established, ongoing        
operations, as well as provide insights into overall demand for its products and
services. To calculate these measures, we exclude from revenue and service      
revenue the effect of the PAD Aviation transaction as there is no prior period  
comparable revenue.                                                             
                                                                                
To calculate adjusted income from operations, adjusted operating margin,        
adjusted net income and adjusted diluted net income per common share, we exclude
certain charges (credits) from GAAP income from operations and GAAP net income, 
such as transaction-related costs, incremental amortization of intangible       
assets, ERP implementation costs, headquarters relocation costs, legal matters  
and discrete tax items. Amounts are presented after-tax using the company's     
statutory tax rate unless the amount is a significant unusual or infrequently   
occurring item in accordance with Financial Accounting Standards Board          
Accounting Standards Codification Topic 740-270-30, "General Methodology and Use
of Estimated Annual Effective Tax Rate.”                                        
                                                                                
* Non-GAAP financial measure.                                                   
                                                                                
Brian Johnston                                                                  
                                                                                
332-895-3222                                                                    
                                                                                
[email protected]                                                       
                                                                                
TransMedics Group, Inc.                                                         
Consolidated Statements of Operations (in thousands, except share and per share
data) · (unaudited)
                                                                                
                       Three Months                    Nine Months              
                     EndedSeptember                 EndedSeptember              
                                30,                            30,              
                               2026        2025               2026        2025  
  Revenue:                                                                      
  Net product              $113,419     $87,677           $332,549    $272,011  
  revenue                                                                       
  Service revenue            89,586      56,146            234,337     172,719  
  Total revenue             203,005     143,823            566,886     444,730  
  Cost of                                                                       
  revenue:                                                                      
  Cost of net                23,570      18,687             73,444      54,420  
  product revenue                                                               
  Cost of service            60,778      40,561            160,426     120,918  
  revenue                                                                       
  Total cost of              84,348      59,248            233,870     175,338  
  revenue                                                                       
  Gross profit              118,657      84,575            333,016     269,392  
  Gross margin                  58%         59%                59%         61%  
  Operating                                                                     
  expenses:                                                                     
  Research,                                                                     
  development and            29,182      15,260             85,693      48,354  
  clinical                                                                      
  trials                                                                        
  Selling,                                                                      
  general and                61,334      46,015            182,149     133,728  
  administrative                                                                
  Total operating            90,516      61,275            267,842     182,082  
  expenses                                                                      
  Income from                28,141      23,300             65,174      87,310  
  operations                                                                    
  Other income                                                                  
  (expense):                                                                    
  Interest                   -7,271      -3,491            -21,666     -10,428  
  expense                                                                       
  Interest income                                                               
  and other                   3,231       3,222              8,483       9,007  
  income                                                                        
  (expense), net                                                                
  Total other                -4,040        -269            -13,183      -1,421  
  expense, net                                                                  
  Income before              24,101      23,031             51,991      85,889  
  income taxes                                                                  
  (Provision)                                                                   
  benefit for                -7,028       1,288            -12,921        -981  
  income taxes                                                                  
  Net income                $17,073     $24,319            $39,070     $84,908  
  Net income per                                                                
  share:                                                                        
  Basic                       $0.49       $0.71              $1.13       $2.50  
  Diluted                     $0.46       $0.66              $1.08       $2.28  
  Weighted                                                                      
  average common                                                                
  shares                                                                        
  outstanding:                                                                  
  Basic                  34,691,046  34,112,452         34,552,868  33,917,006  
  Diluted                40,833,175  40,748,023         36,077,206  40,410,208  
                                                                                
TransMedics Group, Inc. Condensed Consolidated Balance Sheets (in thousands) ·
(unaudited)
                                                                               
                                                  September 30,  December 31,  
                                                           2026          2025  
  Assets                                                                       
  Current assets:                                                              
  Cash                                                 $492,962      $488,366  
  Accounts receivable                                   114,935        84,282  
  Inventory                                              58,373        48,881  
  Prepaid expenses and other current assets              26,186        16,254  
  Total current assets                                  692,456       637,783  
  Property, plant and equipment, net                    376,490       327,656  
  Finance lease right-of-use assets, net                330,400             —  
  Operating lease right-of-use assets, net                4,342         5,155  
  Deferred tax assets                                    72,787        83,543  
  Restricted cash                                        18,438           500  
  Goodwill                                               18,015        11,549  
  Acquired intangible assets, net                         2,815         1,948  
  Other non-current assets                                2,194           239  
  Total assets                                       $1,517,937    $1,068,373  
  Liabilities and Stockholders' Equity                                         
  Current liabilities:                                                         
  Accounts payable                                      $10,143       $10,350  
  Accrued expenses and other current liabilities         82,757        62,740  
  Current portion of long-term debt, net                 54,818        10,000  
  Deferred revenue                                        1,497         2,905  
  Operating lease liabilities                             3,642         3,310  
  Total current liabilities                             152,857        89,305  
  Convertible senior notes, net                         454,994       452,804  
  Long-term debt, net                                         —        49,587  
  Finance lease liability                               351,533             —  
  Operating lease liabilities, net of current             1,915         3,577  
  portion                                                                      
  Other long-term liabilities                             5,926             —  
  Total liabilities                                     967,225       595,273  
  Total stockholders’ equity                            550,712       473,100  
  Total liabilities and stockholders’ equity         $1,517,937    $1,068,373  
                                                                               
TransMedics Group, Inc. Non-GAAP Income From Operations, Net Income and Diluted
Net Income per Share Reconciliations (dollars in thousands, except per share) ·
(unaudited)
                                                                                
  Three Months                                                         Diluted  
  Ended                                                              NetIncome  
  September 30,           Income  OperatingMargin                    perCommon  
  2026            fromOperations  %                Net Income            Share  
 ────────────────────────────────────────────────────────────────────────────── 
  Reported               $28,141  13.9%               $17,073            $0.46  
  Non-GAAP                                                                      
  adjustments:                                                                  
  Transaction-r…             667  0.3%                    667             0.02  
  costs(1)                                                                      
  ERP                                                                           
  implementation              64  0.0%                     48                —  
  costs(2)                                                                      
  Discrete tax                 —  0.0%                  1,125             0.03  
  items(3)                                                                      
  Adjusted               $28,872  14.2%               $18,913            $0.51  
  Nine Months                                                                   
  Ended                                                                         
  September 30,                                                                 
  2026                                                                          
  Reported               $65,174  11.5%               $39,070            $1.08  
  Non-GAAP                                                                      
  adjustments:                                                                  
  Transaction-r…           5,119  0.9%                  3,994             0.10  
  costs(1)                                                                      
  Headquarters                                                                  
  relocation                 272  0.0%                    204             0.01  
  costs(4)                                                                      
  ERP                                                                           
  implementation             309  0.1%                    231             0.01  
  costs(2)                                                                      
  Incremental                                                                   
  amortization                                                                  
  of acquired              1,898  0.3%                  1,418             0.03  
  intangible                                                                    
  assets(5)                                                                     
  Discrete tax                 —  0.0%                  1,125             0.03  
  items(3)                                                                      
  Adjusted               $72,772  12.8%               $46,042           $1.26*  
  * As a result                                                                 
  of our                                                                        
  non-GAAP                                                                      
  adjustments,                                                                  
  our                                                                           
  convertible                                                                   
  senior                                                                        
  notes have a                                                                  
  dilutive                                                                      
  effect for the                                                                
  nine months                                                                   
  ended                                                                         
  September 30,                                                                 
  2026,                                                                         
  for the                                                                       
  purposes of                                                                   
  calculating                                                                   
  adjusted                                                                      
  diluted EPS.                                                                  
  Our adjusted                                                                  
  diluted EPS                                                                   
  includes an                                                                   
  addback of                                                                    
  $5.5 million                                                                  
  of                                                                            
  interest                                                                      
  expense, net                                                                  
  of tax,                                                                       
  attributable                                                                  
  to assumed                                                                    
  conversion of                                                                 
  convertible                                                                   
  senior notes,                                                                 
  and an                                                                        
  inclusion of                                                                  
  an additional                                                                 
  4,893,805                                                                     
  shares to our                                                                 
  diluted                                                                       
  weighted-aver…                                                                
  common shares                                                                 
  outstanding.                                                                  
  Refer                                                                         
  Footnote 10                                                                   
  within our                                                                    
  10-Q filed                                                                    
  with                                                                          
  the SEC on                                                                    
  November 5,                                                                   
  2026 for                                                                      
  additional                                                                    
  details on our                                                                
  net income per                                                                
  share                                                                         
  calculation on                                                                
  a GAAP basis.                                                                 
  Three Months                                                                  
  Ended                                                                         
  September 30,                                                                 
  2025                                                                          
  Reported               $23,300  16.2%               $24,319            $0.66  
  Non-GAAP                                                                      
  adjustments:                                                                  
  Headquarters                                                                  
  relocation                 115  0.1%                     86                —  
  costs(4)                                                                      
  ERP                                                                           
  implementation             156  0.1%                    117             0.01  
  costs(2)                                                                      
  Adjusted               $23,571  16.4%               $24,522            $0.67  
  Nine Months                                                                   
  Ended                                                                         
  September 30,                                                                 
  2025                                                                          
  Reported               $87,310  19.6%               $84,908            $2.28  
  Non-GAAP                                                                      
  adjustments:                                                                  
  Headquarters                                                                  
  relocation                 115  0.0%                     86                —  
  costs(4)                                                                      
  ERP                                                                           
  implementation             156  0.0%                    117             0.01  
  costs(2)                                                                      
  Legal                    2,358  0.6%                  1,759             0.04  
  matters(6)                                                                    
  Adjusted               $89,939  20.2%               $86,870            $2.33  
                                                                                
(1) Transaction-related costs – These adjustments primarily reflect direct and
incremental costs incurred in connection with strategic initiatives and
corporate development activities, and may include due diligence, deal fees,
integration and other fees and costs related to transactions. The Company
excludes only costs that are directly attributable to individually identifiable
transactions that have progressed beyond preliminary evaluation, including those
for which formal internal approvals have been obtained or third-party advisors
have been engaged. Exploratory and other ongoing corporate development and
strategy-related operating expenses are not excluded. Excluded costs
are associated with discrete transaction events and are not reflective of the
Company’s core operating performance, although similar costs may be incurred in
future periods. (2) ERP implementation costs – These adjustments reflect direct
and incremental costs incurred in connection with the design, configuration,
testing, deployment, and initial implementation of a new enterprise resource
planning (“ERP”) system, or a significant upgrade or replacement of an existing
ERP platform. Such costs may include third-party consulting, system integration,
project management, data conversion, and other implementation-related
professional fees. The Company excludes only costs that are directly
attributable to the initial implementation or significant transformation of an
ERP platform and that are non-recurring in nature. Ongoing software
subscription, hosting, maintenance, support, personnel, and other recurring
information technology operating expenses are not excluded. (3) Discrete tax
items – These adjustments represent certain income tax charges or benefits that
management does not consider indicative of ongoing operating performance. Such
items may include the indirect tax consequences of non-GAAP adjustments
affecting the utilization of tax credits, deductions or other tax benefits; tax
effects recognized in the current period related to non-GAAP adjustments
recorded in prior periods; and certain significant tax adjustments arising from
changes in tax laws, valuation allowances, tax settlements or other discrete tax
events, as applicable. These items are excluded from adjusted net income and
adjusted earnings per share to facilitate comparability of operating performance
between periods. (4) Headquarters relocation costs – These adjustments reflect
primarily direct and incremental third-party professional fees, including
valuation, accounting, and advisory services, incurred in connection with the
Company’s relocation of its headquarters to Somerville, Massachusetts. These
costs may also include incremental depreciation of fixed assets resulting from
reassessments of estimated economic lives in consideration of the relocation.
The Company excludes only costs that are directly attributable to the relocation
event and does not exclude ongoing occupancy, personnel, or other recurring
operating expenses associated with the new headquarters. (5) Incremental
amortization of acquired intangible assets – We record intangible assets
acquired in a business combination or asset acquisition at acquisition date fair
values and amortize over their estimated useful lives. These adjustments reflect
non-cash charges related to incremental amortization of acquired intangible
assets, resulting from periodic reassessments of estimated economic lives. These
amounts are excluded as they relate to discrete, non-routine activities rather
than the Company’s ongoing operations and therefore are not considered
indicative of normal operating costs. (6) Legal matters - These adjustments
reflect legal fees and other directly attributable costs incurred in connection
with responding to and addressing matters arising from the short-seller report
issued in January 2025. Such costs may include external legal counsel, advisory
services, and other incremental expenses necessary to evaluate and defend
against the claims. The Company excludes only costs that are specifically
associated with this discrete event and does not exclude ongoing legal expenses
related to normal business operations. These costs are excluded as they are non-
recurring in nature and not indicative of the Company’s core operating
performance, although similar costs could arise in future periods. (7)
Reconciliation of revenue to organic revenue and of service revenue to organic
service revenue (dollars in thousands) (unaudited).
                                                                                
  Three Months                                                                  
  Ended                                                         Service         
  September 30,                Revenue Growth                   Revenue Growth  
  2026           TotalRevenue  %               Service Revenue  %               
 ────────────────────────────────────────────────────────────────────────────── 
  Reported           $203,005  41.1%                   $89,586  59.6%           
  Less: PAD                                                                     
  Aviation              9,385  6.5%                      9,385  16.8%           
  charter                                                                       
  services                                                                      
  Organic            $193,620  34.6%                   $80,201  42.8%           
  Nine Months                                                                   
  Ended                                                                         
  September 30,                                                                 
  2026                                                                          
  Reported           $566,886  27.5%                  $234,337  35.7%           
  Less: PAD                                                                     
  Aviation              9,385  2.1%                      9,385  5.5%            
  charter                                                                       
  services                                                                      
  Organic            $557,501  25.4%                  $224,952  30.2%           
                                                                                
(8) Full-Year 2026 Revenue Guidance: Revenue guidance of $764-$774 million, less
expected PAD Aviation revenue of approximately $14 million, equals revenue
guidance excluding PAD Aviation* of $750-$760 million.

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TMDX/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.